• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

ECTRIMS 2018 DAILY REPORT – WEDNESDAY EDITION

October 10, 2018  

ECTRIMS Poster Picks – Wednesday, October 10

October 10, 2018  

Laquinimod program cancelled in MS

September 6, 2018  

Heart disease associated with atrophy in MS

August 15, 2018  

Predictors of switching therapies in MS – real-world results

August 1, 2018  

Exploring therapeutic inertia in multiple sclerosis

July 11, 2018  

Update on oral cladribine – Effect on lymphocytes and safety data

May 9, 2018  

MS therapeutics: 1 withdrawal, 1 setback

March 5, 2018  

DMF: the Canadian MS patient experience

February 28, 2018  

ECTRIMS/EAN publish new MS treatment guidelines

January 30, 2018  
Previous
24
25
26
27
28
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions